BamSEC and AlphaSense Join Forces
Learn More

Arrowhead Pharmaceuticals Inc.

NASDAQ: ARWR    
Share price (8/13/25): $19.99    
Market cap (8/13/25): $2.764 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.6
from 10-Q 7 pages Material contract
12/34/56
EX-10.5
from 10-Q 1 page R From the Desk Of: Patrick O’brien Chief Operating Officer and General Counsel May 9, 2025 Ken Myszkowski, CFO Arrowhead Pharmaceuticals, Inc. Regards, /S/ Patrick O’brien Patrick O’brien Accepted: /S/ Ken Myszkowski Ken Myszkowski 177 E. Colorado Blvd. Suite 700 Pasadena, Ca 91105 WWW.ARROWHEADPHARMA.com
12/34/56
EX-10.4
from 10-Q 13 pages Severance and Change of Control Agreement
12/34/56
EX-10.3
from 10-Q 13 pages Severance and Change of Control Agreement
12/34/56
EX-10.2
from 10-Q 13 pages Severance and Change of Control Agreement
12/34/56
EX-10.1
from 10-Q 13 pages Severance and Change of Control Agreement
12/34/56
EX-10.4
from 10-Q 152 pages Material contract
12/34/56
EX-10.3
from 10-Q 106 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Exclusive License and Collaboration Agreement by and Between Arrowhead Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. November 25, 2024
12/34/56
EX-10.49
from 10-K 48 pages Material contract
12/34/56
EX-10.48
from 10-K 70 pages Material contract
12/34/56
EX-10.1
from 10-Q 10 pages Material contract
12/34/56
EX-10.1
from 10-Q 97 pages Material contract
12/34/56
EX-10.39
from 10-K 4 pages Material contract
12/34/56
EX-10.11
from 10-K 7 pages Material contract
12/34/56
EX-10.9
from 10-K 5 pages Material contract
12/34/56
EX-10.7
from 10-K 5 pages Material contract
12/34/56
EX-10.1
from 10-Q 43 pages Royalty Purchase Agreement by and Between Arrowhead Pharmaceuticals, Inc. and Royalty Pharma Investments 2019 Icav Dated as of November 9, 2022
12/34/56
EX-10.1
from 10-Q 7 pages Recitals Agreement
12/34/56
EX-10.6
from 10-Q 12 pages Separation and Release of Claims Agreement
12/34/56
EX-10.2
from 10-Q 50 pages Lease Agreement
12/34/56